Douglas Easton
Vice President for Healthcare Outcomes Policy and
Oncology and Molecular Radiation Sciences
University of London, UK
Norway
Biography
Professor Douglas Easton is currently Director of the Centre for Cancer Genetic Epidemiology within the Department of Public Health and Primary Care. He studied Mathematical Statistics at the University of Cambridge before gaining a PhD in Genetic Epidemiology at the University of London in 1992. In 1995 he set up the Cancer Research UK Genetic Epidemiology Unit at Cambridge, where he was a CR-UK Principal Research Fellow from 2001-2011. He was awarded Professorship of Genetic Epidemiology in 2003.
Research Interest
The main research interest of the Centre is in genetic susceptibility to common cancers and the aim of Professor Easton’s research group is to identify and characterise genetic variants associated with cancer risk, with particular emphasis on the hormone related cancers. Much of their recent work has focused on the analysis of genome-wide association studies (GWAS) to characterise common susceptibility variants, and the characterisation of susceptibility loci through fine-mapping. The group has conducted GWAS in breast cancer, prostate, endometrial and testis cancer. Prof Easton’s group also co-ordinates three large international consortia: the Breast Cancer Association Consortium (BCAC), Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome
Publications
-
Michailidou K, et al…Easton DF (2015) Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet. 2015;47(4):373-80. PubMed ID: 25751625 Milne RL, et al …Easton DF (2014) A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46 450 cases and 42 461 controls from the breast cancer association consortium. Hum Mol Genet 23 (7): 1934-1946 PubMed ID: 24242184 Mavaddat N, et all…Easton DF (2013) Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE. J Natl Cancer Inst 105 (11): 812-822 PubMed ID: 23628597 Michailidou K, et al …Easton DF (2013) Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 45 : 353-361 PubMed ID: 23535729
-
Lee, A., et al… (2016) Incorporating Truncating Variants in PALB2, CHEK2 and ATM into the BOADICEA Breast Cancer Risk Model. Genetics In Medicine net Med. 2016 Apr 14. 2016 Dec;18(12):1190-1198. Pubmed ID: 27464310 Dunning A., et al … (2016) Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170, Nature Genetics 48(4):374-86 PubMed ID: 26928228 Easton, D.F., et al… (2015) Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk. N Engl J Med Jun 4;372(23):2243-57 PubMed ID: 26014596 Mavaddat N, et al… (2015) Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst. Apr 8;107(5) PubMed ID 25855707
